{"id":448953,"date":"2021-03-02T16:33:25","date_gmt":"2021-03-02T21:33:25","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=448953"},"modified":"2021-03-02T16:33:25","modified_gmt":"2021-03-02T21:33:25","slug":"stealth-biotherapeutics-to-present-at-upcoming-investor-conferences-in-march","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/stealth-biotherapeutics-to-present-at-upcoming-investor-conferences-in-march\/","title":{"rendered":"Stealth BioTherapeutics to Present at Upcoming Investor Conferences in March"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">BOSTON<\/span>, <span class=\"xn-chron\">March 2, 2021<\/span> \/PRNewswire\/ &#8212;\u00a0Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that <span class=\"xn-person\">Reenie McCarthy<\/span>, CEO, will present at the following upcoming virtual investor conferences in March:<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/969361\/Stealth_BioTherapeutics_Logo.html\" target=\"_blank\" rel=\"nofollow noopener noreferrer\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/969361\/Stealth_BioTherapeutics_Logo.jpg\" title=\"Stealth BioTherapeutics Logo (PRNewsFoto\/Stealth BioTherapeutics) (PRNewsfoto\/Stealth BioTherapeutics)\" alt=\"Stealth BioTherapeutics Logo (PRNewsFoto\/Stealth BioTherapeutics) (PRNewsfoto\/Stealth BioTherapeutics)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>\n        <b>H.C. Wainwright Global Life Sciences Conference<br \/><\/b>Date: <span class=\"xn-chron\">Tuesday, March 9, 2021<\/span><br \/>Time: <span class=\"xn-chron\">7:00 a.m. ET<\/span><\/p>\n<p>\n        <b>Oppenheimer&#8217;s 31st Annual Healthcare Conference<br \/><\/b>Date: <span class=\"xn-chron\">Wednesday, March 17, 2021<\/span><br \/>Time: <span class=\"xn-chron\">10:40 am ET<\/span><\/p>\n<p>A live audio webcast of the presentations will be available on the Investors &amp; News section of Stealth&#8217;s website at\u00a0<a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3083744-1&amp;h=1576107210&amp;u=https%3A%2F%2Finvestor.stealthbt.com%2F&amp;a=https%3A%2F%2Finvestor.stealthbt.com%2F\" rel=\"nofollow noopener noreferrer\">https:\/\/investor.stealthbt.com\/<\/a>. A replay of the webcasts will be archived on Stealth&#8217;s website for 30 days following the event.<\/p>\n<p>\n        <b>About Stealth<br \/><\/b>We are a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction. Mitochondria, found in nearly every cell in the body, are the body&#8217;s main source of energy production and are critical for normal organ function. Dysfunctional mitochondria characterize a number of rare genetic diseases and are involved in many common age-related diseases, typically involving organ systems with high energy demands such as the heart, the eye, and the brain. We believe our lead product candidate, elamipretide, has the potential to treat both rare metabolic cardiomyopathies, such as Barth, Duchenne muscular dystrophy and Friedreich&#8217;s ataxia, rare mitochondrial diseases entailing nuclear DNA mutations, such as POLG-related disorders, as well as ophthalmic diseases entailing mitochondrial dysfunction, such as dry AMD and Leber&#8217;s hereditary optic neuropathy. We are evaluating our second-generation clinical-stage candidate, SBT-272, and our new series of small molecules, SBT-550, for rare neurological disease indications following promising preclinical data. We have optimized our discovery platform to identify novel mitochondria-targeted compounds which may be nominated as therapeutic product candidates or utilized as scaffolds to deliver other compounds to mitochondria.<\/p>\n<p>\n        <b>Investor Relations<br \/><\/b>Stern Investor Relations<br \/><span class=\"xn-person\">Janhavi Mohite<\/span>, 212-362-1200<br \/><a target=\"_blank\" href=\"mailto:IR@StealthBT.com\" rel=\"nofollow noopener noreferrer\">IR@StealthBT.com<\/a>\u00a0<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder2\"><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=NE96075&amp;sd=2021-03-02\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/stealth-biotherapeutics-to-present-at-upcoming-investor-conferences-in-march-301238949.html\">http:\/\/www.prnewswire.com\/news-releases\/stealth-biotherapeutics-to-present-at-upcoming-investor-conferences-in-march-301238949.html<\/a><\/p>\n<p>SOURCE  Stealth BioTherapeutics Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=NE96075&amp;Transmission_Id=202103021630PR_NEWS_USPR_____NE96075&amp;DateId=20210302\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire BOSTON, March 2, 2021 \/PRNewswire\/ &#8212;\u00a0Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that Reenie McCarthy, CEO, will present at the following upcoming virtual investor conferences in March: H.C. Wainwright Global Life Sciences ConferenceDate: Tuesday, March 9, 2021Time: 7:00 a.m. ET Oppenheimer&#8217;s 31st Annual Healthcare ConferenceDate: Wednesday, March 17, 2021Time: 10:40 am ET A live audio webcast of the presentations will be available on the Investors &amp; News section of Stealth&#8217;s website at\u00a0https:\/\/investor.stealthbt.com\/. A replay of the webcasts will be archived on Stealth&#8217;s website for 30 days following the event. About StealthWe are a clinical-stage biotechnology company focused on the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/stealth-biotherapeutics-to-present-at-upcoming-investor-conferences-in-march\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Stealth BioTherapeutics to Present at Upcoming Investor Conferences in March&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-448953","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Stealth BioTherapeutics to Present at Upcoming Investor Conferences in March - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/stealth-biotherapeutics-to-present-at-upcoming-investor-conferences-in-march\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Stealth BioTherapeutics to Present at Upcoming Investor Conferences in March - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire BOSTON, March 2, 2021 \/PRNewswire\/ &#8212;\u00a0Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that Reenie McCarthy, CEO, will present at the following upcoming virtual investor conferences in March: H.C. Wainwright Global Life Sciences ConferenceDate: Tuesday, March 9, 2021Time: 7:00 a.m. ET Oppenheimer&#8217;s 31st Annual Healthcare ConferenceDate: Wednesday, March 17, 2021Time: 10:40 am ET A live audio webcast of the presentations will be available on the Investors &amp; News section of Stealth&#8217;s website at\u00a0https:\/\/investor.stealthbt.com\/. A replay of the webcasts will be archived on Stealth&#8217;s website for 30 days following the event. About StealthWe are a clinical-stage biotechnology company focused on the &hellip; Continue reading &quot;Stealth BioTherapeutics to Present at Upcoming Investor Conferences in March&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/stealth-biotherapeutics-to-present-at-upcoming-investor-conferences-in-march\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-02T21:33:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/969361\/Stealth_BioTherapeutics_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/stealth-biotherapeutics-to-present-at-upcoming-investor-conferences-in-march\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/stealth-biotherapeutics-to-present-at-upcoming-investor-conferences-in-march\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Stealth BioTherapeutics to Present at Upcoming Investor Conferences in March\",\"datePublished\":\"2021-03-02T21:33:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/stealth-biotherapeutics-to-present-at-upcoming-investor-conferences-in-march\\\/\"},\"wordCount\":345,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/stealth-biotherapeutics-to-present-at-upcoming-investor-conferences-in-march\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/969361\\\/Stealth_BioTherapeutics_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/stealth-biotherapeutics-to-present-at-upcoming-investor-conferences-in-march\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/stealth-biotherapeutics-to-present-at-upcoming-investor-conferences-in-march\\\/\",\"name\":\"Stealth BioTherapeutics to Present at Upcoming Investor Conferences in March - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/stealth-biotherapeutics-to-present-at-upcoming-investor-conferences-in-march\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/stealth-biotherapeutics-to-present-at-upcoming-investor-conferences-in-march\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/969361\\\/Stealth_BioTherapeutics_Logo.jpg\",\"datePublished\":\"2021-03-02T21:33:25+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/stealth-biotherapeutics-to-present-at-upcoming-investor-conferences-in-march\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/stealth-biotherapeutics-to-present-at-upcoming-investor-conferences-in-march\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/stealth-biotherapeutics-to-present-at-upcoming-investor-conferences-in-march\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/969361\\\/Stealth_BioTherapeutics_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/969361\\\/Stealth_BioTherapeutics_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/stealth-biotherapeutics-to-present-at-upcoming-investor-conferences-in-march\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Stealth BioTherapeutics to Present at Upcoming Investor Conferences in March\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Stealth BioTherapeutics to Present at Upcoming Investor Conferences in March - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/stealth-biotherapeutics-to-present-at-upcoming-investor-conferences-in-march\/","og_locale":"en_US","og_type":"article","og_title":"Stealth BioTherapeutics to Present at Upcoming Investor Conferences in March - Market Newsdesk","og_description":"PR Newswire BOSTON, March 2, 2021 \/PRNewswire\/ &#8212;\u00a0Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that Reenie McCarthy, CEO, will present at the following upcoming virtual investor conferences in March: H.C. Wainwright Global Life Sciences ConferenceDate: Tuesday, March 9, 2021Time: 7:00 a.m. ET Oppenheimer&#8217;s 31st Annual Healthcare ConferenceDate: Wednesday, March 17, 2021Time: 10:40 am ET A live audio webcast of the presentations will be available on the Investors &amp; News section of Stealth&#8217;s website at\u00a0https:\/\/investor.stealthbt.com\/. A replay of the webcasts will be archived on Stealth&#8217;s website for 30 days following the event. About StealthWe are a clinical-stage biotechnology company focused on the &hellip; Continue reading \"Stealth BioTherapeutics to Present at Upcoming Investor Conferences in March\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/stealth-biotherapeutics-to-present-at-upcoming-investor-conferences-in-march\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-02T21:33:25+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/969361\/Stealth_BioTherapeutics_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/stealth-biotherapeutics-to-present-at-upcoming-investor-conferences-in-march\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/stealth-biotherapeutics-to-present-at-upcoming-investor-conferences-in-march\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Stealth BioTherapeutics to Present at Upcoming Investor Conferences in March","datePublished":"2021-03-02T21:33:25+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/stealth-biotherapeutics-to-present-at-upcoming-investor-conferences-in-march\/"},"wordCount":345,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/stealth-biotherapeutics-to-present-at-upcoming-investor-conferences-in-march\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/969361\/Stealth_BioTherapeutics_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/stealth-biotherapeutics-to-present-at-upcoming-investor-conferences-in-march\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/stealth-biotherapeutics-to-present-at-upcoming-investor-conferences-in-march\/","name":"Stealth BioTherapeutics to Present at Upcoming Investor Conferences in March - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/stealth-biotherapeutics-to-present-at-upcoming-investor-conferences-in-march\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/stealth-biotherapeutics-to-present-at-upcoming-investor-conferences-in-march\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/969361\/Stealth_BioTherapeutics_Logo.jpg","datePublished":"2021-03-02T21:33:25+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/stealth-biotherapeutics-to-present-at-upcoming-investor-conferences-in-march\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/stealth-biotherapeutics-to-present-at-upcoming-investor-conferences-in-march\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/stealth-biotherapeutics-to-present-at-upcoming-investor-conferences-in-march\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/969361\/Stealth_BioTherapeutics_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/969361\/Stealth_BioTherapeutics_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/stealth-biotherapeutics-to-present-at-upcoming-investor-conferences-in-march\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Stealth BioTherapeutics to Present at Upcoming Investor Conferences in March"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/448953","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=448953"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/448953\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=448953"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=448953"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=448953"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}